U.S. Markets open in 12 mins

Interviews with CEO Denis Corin of Q BioMed and CEO George Nikopoulos of Mannin Research

NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announces multiple interviews with the company’s CEO, Denis Corin, and the Q BioMed team are now available.

An exclusive video interview with Chairman and CEO Denis Corin from the NASDAQ MarketSite. Mr. Corin discusses Q BioMed developments and updates and the upcoming catalyst for 2019. Please click here to watch the full interview.

Denis Corin joins Olivia Voznenko from Modern Wall Street. Mr. Corin talks about Q BioMed and highlighting business & product development in cancer and autism. Please click here to watch the full interview.

See the latest Beehind the Buzz Show: Featuring Q BioMed Inc. Chairman and Chief Executive Officer Denis Corin at last week’s BIO CEO Investor Conference in New York. Please click here to watch the full interview.

George Nikopoulos, CEO of Mannin Research, discusses Mannin's MAN-01 therapeutic which has the opportunity to be a first-in-class drug for Intraocular Eye Pressure, the only drug targeting the critical ‘Schlemms’ Canal. Dr Nikopoulos also discusses a novel biomarker the company has an interest in, that will help physicians detect disease progression and treatment options. Please click here to watch the full video

About Q BioMed Inc.

Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019.  Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.

For more information please visit www.qbiomed.com.


Forward Looking Statements:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Denis Corin  
CEO  
Q BioMed Inc. 
+1(646)884-7017